Mark C. Schneyer - Aug 16, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Aug 16, 2024
Transactions value $
-$148,720
Form type
4
Date filed
8/20/2024, 06:46 PM
Previous filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Award $0 +5.28K +15.26% $0.00 39.8K Aug 16, 2024 Direct F1
transaction ACAD Common Stock Award $0 +13.6K +34.21% $0.00 53.5K Aug 16, 2024 Direct F2
transaction ACAD Common Stock Sale -$149K -9.73K -18.2% $15.28 43.7K Aug 19, 2024 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
F2 Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
F3 The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.